While there are few long‐term data regarding CRC risk reduction with anti‐TNF agents, a 2011 Dutch case–control study of 173 cases of IBD‐associated CRC found a significant reduction in CRC risk with the use of infliximab, with an odds ratio of 0.09.16, 17. The gene discussed is TNF; the disease is inflammatory bowel disease.